 |
 |
| Home |
| Clinical Trial Search |
| Mailing List |
| Clinical Trial FAQs |
| Participation FAQs |
| Clinical Trials Glossary |
| About Informed Consent |
| Medical Research Areas |
| Clinical Trial Links |
|
This site is intended for U.S. residents only. For Novartis Worldwide, Click here |
|
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
|
|
|
|
|||
Clinical Trial Search
High Blood Pressure
Also known as hypertension (hi-per-TEN-shun), this condition usually causes no symptoms, unless the pressure gets extremely high; it's therefore often called the "silent killer". Over time the elevated pressure causes damage to the blood vessels and to the organs the vessels supply with blood. This can result in stroke, heart attack, kidney failure, heart failure and damage to the eye, called retinopathy.
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. How to use this system:The purpose of this system is to help connect interested study participants with clinical research centers. The following is a brief outline explaining the main steps involved in using this system. Please note that every step in this process is optional.
1. Select a clinical trial that you feel best suits your (or the participant's)
health condition. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Hypertension Study CVAA489AUS02
The purpose of this clinical research study is to compare the medium dose of an FDA approved combination drug with the higher dose of an FDA approved combination drug on blood pressure control in patients who have failed to have their blood pressure controlled on a single antihypertensive agent. An FDA approved combination drug in this instance is referring to, two antihypertensive medications in one pill that has been tested and is approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 4 Participation Duration: The study will last at least 13 weeks with participants required to visit the study center at least 6 times but up to 7 times. Some participants will be asked to wear an ambulatory blood pressure monitoring device for approximately 24 hours at 3 visits. Wearing this device involves fastening it to the side of the body and placing a cuff around the arm. The cuff automatically inflates and deflates several times per hour to measure blood pressure. These participants will come to the study center 9 times over 17 weeks. Protocol Number: CVAA489AUS02 Hypertension Study CSPP100A2353
The purpose of this clinical research study is to determine if the FDA-approved study drug aliskiren alone (Rasilez®/Tekturna®) or if the mix (combination) of two FDA-approved study drugs aliskiren and hydrochlorothiazide (Tekturna-HCT®) is safe and has beneficial effects in people who have moderate hypertension (high blood pressure). Participants must be at least 18 years old and have moderate hypertension and will be asked to visit the study center 6 times over a 14 to 16 week period. Rasilez®, Tekturna® and Tekturna-HCT® have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of high blood pressure.
Trial phase: Phase 3b Participation Duration: The participant would be required to visit the study center 6 times over a 14 to 16 week period. Protocol Number: CSPP100A2353
Hypertension Study CVAH631BUS08
The purpose of this clinical research study is to determine the efficacy and safety of the combination of the study drug valsartan plus hydrochlorothiazide (known as Diovan HCT®) compared to patients initiated with either valsartan or hydrochlorothiazide. Participants must be at least 75 years old and have high blood pressure and will be asked to visit the study center 8 to 10 times over a 16 week period.
Diovan HCT® has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of high blood pressure.
Trial phase: Phase 4 Participation Duration: Participants will be required to visit the study center 8 to 10 times over a 16 week period. Protocol Number: CVAH631BUS08 Hypertension Study CSPP100AUS03
The purpose of this clinical research study is to find out if the study drug aliskiren HCTZ is safe and has a beneficial effect when compared to amlodipine in African-American people who have high blood pressure. Participants must be at least 18 years old, and have high blood pressure. Aliskiren HCTZ and amlodipine have individually been approved by the U.S. Food and Drug Administration (FDA) for the treatment of high blood pressure.
Trial phase: Phase 4 Participation Duration: Participants will be required to visit the study center a maximum of 8 times over 12 weeks. Each visit should take about 1-2 hours. Protocol Number: CSPP100AUS03
Hypertension Study CSAH100A2301
The purpose of this clinical research study is to find out if the combination of aliskiren, amlodipine and hydrochlorothiazide (HCTZ) is safe for long-term use in lowering blood pressure for participants. Participants must be at least 18 years old and have high blood pressure. The combination of aliskiren, amlodipine, and HCTZ is considered investigational which means that it is still being tested and is not approved by the Health authorities.
Trial phase: Phase 3 Participation Duration: Participants will be required to visit the study center 10 times over a 28 week period. Each visit will take about 1 hour. After the initial 28 weeks, the participant will be evaluated by the doctor to determine their ability to participate in a subsequent 26 week study. If eligible, the participant will be required to visit the study center 2 times over the additional 26 week period. Protocol Number: CSAH100A2301 |
